EnerSpar Corp. (TSE:NRX) has released an update.
NurExone Biologic Inc. has announced a significant stride in regenerative medicine by partnering with a German GMP manufacturer for the production of their ExoPTEN nanodrug’s active siRNA element. This collaboration is set to meet the high-quality standards necessary for clinical trials and potential commercialization. The new GMP-manufactured siRNA has demonstrated comparable effectiveness in reducing PTEN expression, crucial for nerve regeneration therapies.
For further insights into TSE:NRX stock, check out TipRanks’ Stock Analysis page.
